

Review

The Role of Psychedelics in Treating Psychiatric Disorders

Sneha Lata¹, S.G. Mehta², Khushboo Jain³ and Urvi Gaur^{4*}¹Assistant Professor, ²Professor and Head, ³Senior Resident, ⁴Post Graduate Student
Department of Psychiatry, Pacific Medical College and Hospital, Udaipur, Rajasthan, Bharat

Received : 05 March 2025

Revised : 09 March 2025

Accepted : 15 March 2025

*Corresponding Author Email: urvigaur29@gmail.com

ABSTRACT

Mental health disorders pose a significant global challenge, with traditional treatments such as psychotherapy and antidepressants often proving insufficient for many patients. In recent years, psychedelics have re-emerged as a promising alternative, offering potential breakthroughs in treating conditions like treatment-resistant depression, anxiety, PTSD, and addiction. Historically, psychedelics have been used in medical and religious contexts for centuries, but their therapeutic exploration was hindered by legal restrictions and societal stigma in the 20th century. Recent advancements in neuroscience and neuroimaging have reignited interest, revealing that psychedelics interact with serotonin receptors to induce altered states of consciousness, disrupt rigid thought patterns, and promote cognitive flexibility. Clinical trials, particularly with psilocybin, have demonstrated sustained antidepressant effects and therapeutic potential when administered in controlled settings. However, ethical and legal challenges, including stigma and regulatory barriers, must be addressed to ensure safe and effective implementation. Future research should focus on understanding the neurobiological mechanisms, long-term effects, and integration of psychedelics into mental health care, fostering a multidisciplinary approach to harness their full therapeutic potential. This paper explores the historical context, neurobiological mechanisms, current research, and ethical considerations surrounding psychedelics, highlighting their transformative role in mental health treatment.

KEYWORDS: Psychedelics, Mental health disorders, Treatment-resistant depression, PTSD, Anxiety, Psilocybin, Neurobiological mechanisms

INTRODUCTION

Mental health significantly impacts an individual's life, and treating mental illnesses effectively remains a challenge. Recent research has highlighted the potential of psychedelics as an alternative treatment with promising outcomes. Since the late 1980s, dedicated researchers have explored the effects of psychedelics. In light of a growing

global mental health crisis, interest in alternative treatments has surged. For decades, mental health disorders have primarily been treated with psychotherapy and antidepressants. However, 20% of patients report no improvement after trying various antidepressants over extended periods. This underscores the need for innovative and alternative approaches, which appear highly promising¹.

Historically, psychedelics have been portrayed in literature and films, often associated with countercultural figures, artists, and spiritual seekers. This societal perception has influenced research, creating a psychosocial bias. Additionally, strict legal regulations have hindered the study of psychedelics. However, recent scientific breakthroughs have reignited interest in these substances, justifying their potential therapeutic use. For instance, psilocybin, a compound found in magic mushrooms, has shown encouraging results in treating treatment-resistant depression, as well as alleviating anxiety and depression. This paper will explore the historical context of psychedelics, their therapeutic effects, the neurobiological mechanisms underlying their impact, and the ethical considerations surrounding their use. Finally, it will reflect on recent insights from early researchers and discuss future directions in this field².

HISTORICAL CONTEXT OF PSYCHEDELICS IN MEDICINE

Psychedelics, or hallucinogens, have been used in medical and religious practices for centuries. These substances induce altered states of consciousness, often leading to mystical or ecstatic experiences. Indigenous groups in South America, North America, and Africa have used psychedelics as sacramental tools for thousands of years. In the 1950s, advances in neuroscience led to the synthesis of new drugs with properties similar to natural compounds like serotonin and mescaline. Researchers often self-experimented, and psychedelics were studied for their potential to treat psychiatric conditions, driven by reports of altered consciousness and "mind expansion".

Psychedelics inspired alternative models for understanding psychopathology, diverging from traditional animal models and psychometrics. They were used to treat various psychiatric disorders, including depression and neurotic conditions, and to predict treatment outcomes. However, their use in psychotherapy became controversial in the 1970s, leading to strict regulations by the U.S. Drug Enforcement Administration and the World Health Organization, which classified them as having medical potential but restricted their use. Research on psychedelics declined for over three decades due to legal restrictions, political issues, and funding cuts. However, interest revived in the late 1990s as regulations eased, enabling clinical trials and laboratory research. Pharmaceutical companies began developing FDA-compliant psychedelics, leading to the first Phase 1 and Phase 2 trials in decades. Major academic institutions and funding agencies have since supported research into psychedelics for treating addiction, depression, and PTSD, attracting interdisciplinary interest from social scientists, historians, and neuroscientists³.

NEUROBIOLOGICAL MECHANISMS OF PSYCHEDELICS IN MENTAL HEALTH TREATMENT

Understanding the neurobiological effects of psychedelics is crucial for their application in mental health treatment. Research focuses on the biological changes these substances induce in the brain rather than underlying pathologies. At a molecular level, psychedelics interact with the serotonin receptor system, which plays a key role in regulating mood disorders. The subjective effects of psychedelics, such as altered sensory perceptions and moments of cognitive clarity, provide insights into their therapeutic potential. The setting in which psychedelics are administered—encompassing the physical and social environment, including the therapist and a calming, aesthetically pleasing space—also influences their effects⁴.

Since 2006, neuroimaging studies using MRI and PET scans have been conducted during the administration of psilocybin, LSD, ketamine, and DMT in clinical settings. Although sample sizes are small, the data consistently suggest that psychedelics may reduce symptoms of mental health disorders by disrupting rigid self-narratives and opening individuals to new perspectives. This process is akin to a retreat, offering a break from habitual thought patterns and fostering a sense of connection with the external world. Without these perceptual shifts, therapeutic withdrawal would not be possible⁵.

CURRENT RESEARCH AND CLINICAL TRIALS ON PSYCHEDELICS FOR MENTAL HEALTH DISORDERS

Recent years have seen a resurgence of interest in psychedelics for treating mental health disorders. Studies have demonstrated the potential of substances like psilocybin to alleviate symptoms of treatment-resistant depression, PTSD, anxiety, addiction, and schizophrenia. Open-label studies have shown that psilocybin, combined with therapy, can produce sustained antidepressant effects. This growing evidence base has led to legislative changes, such as the rescheduling of psilocybin in Australia for specific mental health indications⁶.

The potential of psychedelics has only recently regained attention in mental health research. Regulatory changes in several countries have facilitated rigorous clinical trials, aiming to make these substances available for therapeutic use. Research institutions worldwide are increasingly supporting psychedelic-based therapeutics, with Australia emerging as a key player through clinical trials and preclinical research⁷.

ETHICAL AND LEGAL CONSIDERATIONS IN THE USE OF PSYCHEDELICS FOR MENTAL HEALTH TREATMENT

The use of psychedelics in mental health treatment raises significant ethical and legal issues. Stigmatization of psychiatric disorders remains a barrier, as societal biases can hinder therapeutic progress and patient participation⁸. Regulatory challenges also exist, with stringent pharmaceutical regulations requiring extensive safety and risk assessments before approval. Patient welfare is the primary concern, and psychedelic research aims to develop treatments for conditions where existing therapies fall short⁹. Collaboration among clinicians, researchers, legal professionals, and regulatory authorities is essential to create an ethical and effective framework for psychedelic-assisted therapy¹⁰.

CONCLUSIONS AND FUTURE DIRECTIONS

Psychedelics represent a promising approach to addressing the global burden of mental health disorders. Research and clinical trials suggest that these substances can provide rapid and significant relief for treatment-resistant conditions. While psychedelics have a long and complex history, their therapeutic potential has moved beyond subcultural enthusiasm to become a legitimate area of scientific inquiry. Future research should focus on understanding the acute and long-term effects of psychedelics, integrating findings from neuroimaging, molecular neuroscience, and genetics to develop biologically informed treatments. Preclinical models will also play a crucial role in elucidating the mechanisms underlying psychedelics' effects, ultimately advancing translational research and improving clinical outcomes. This multidisciplinary approach will pave the way for the responsible and effective use of psychedelics in mental health care.

CONFLICT OF INTEREST: None

FINANCIAL SUPPORT: None

REFERENCES

1. Arnout, B., Alkhatib, A., 2019. The secret of human existence homeostasis: spiritual intelligence is the hope of all humanity. *Open Access J. Addict. Psychol.*, 2(3): 1-9.
2. Arnout, B., Alkhatib, A., Abdel Rahman, D., Pavlovic, S., Al-Dabbagh, Z., Latyshev, O., 2019a. Spiritual intelligence and self affirmation as predictors of athletes' psychological well-being. *Int. J. Appl. Psychol.*, 9(4): 104-109.
3. Arnout, B., Latyshev, O., Alkhatib, A., 2019b. The relative contribution of spiritual intelligence in the adherence to research ethical standards. *Biomed. J. Sci. Tech. Res.*, 18(5): 13917-13927.
4. Borroto-Escuela, D.O., Ambrogini, P., Narvaez, M., Di Liberto, V., Beggiato, S., Ferraro, L., Fores-Pons, R., Alvarez-Contino, J.E., Lopez-Salas, A., Mudò, G., 2021. Serotonin heteroreceptor complexes and their integration of signals in neurons and Astroglia—relevance for mental diseases. *Cells.*, 10(8): 1902.
5. Brecksema, J.J., Niemeijer, A.R., Krediet, E., Vermetten, E., Schoevers, R.A., 2020. Psychedelic treatments for psychiatric disorders: A systematic review and thematic synthesis of patient experiences in qualitative studies. *CNS Drugs.*, 34: 925-946.
6. Castelhana, J., Lima, G., Teixeira, M., Soares, C., Pais, M., Castelo-Branco, M., 2021. The effects of tryptamine psychedelics in the brain: a meta-analysis of functional and review of molecular imaging studies. *Front. Pharmacol.*, 12: 739053.
7. Celidwen, Y., Redvers, N., Githaiga, C., Calambás, J., Añaños, K., Chindoy, M.E., Vitale, R., Rojas, J.N., Mondragón, D., Rosalío, Y.V., 2023. Ethical principles of traditional Indigenous medicine to guide western psychedelic research and practice. *Lancet. Reg. Health. Am.*, 18. Chi, T., Gold, J.A., 2020. A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses. *J. Neurol. Sci.*, 411: 116715.
8. Colloca, L., Fava, M., 2024. What should constitute a control condition in psychedelic drug trials? *Nat. Ment. Health.*, 2(10): 1152-1160.
9. Császár-Nagy, N., Bob, P., Bókkon, I., 2022. A multidisciplinary hypothesis about serotonergic psychedelics. Is it possible that a portion of brain serotonin comes from the gut? *J. Integr. Neurosci.*, 21(5): 148.
10. Cumming, P., Scheidegger, M., Dornbierer, D., Palner, M., Quednow, B.B., Martin-Soelch, C., 2021. Molecular and functional imaging studies of psychedelic drug action in animals and humans. *Molec., (Basel, Switzerland)*, 26(9): 2451.